BridgeBio Oncology Therapeutics Inc.

BridgeBio Oncology Therapeutics is rated Speculative Buy, with a risk-adjusted valuation of $3.76 per share, implying 33% upside. BBOT's pipeline, led by BBO-11818, targets multiple KRAS mutations and offers potential differentiation over existing KRAS G12C inhibitors. Recent strategic shifts and clinical updates triggered a 68% decline in BBOT's stock, reflecting concerns about commercial scope and execution.

SOUTH SAN FRANCISCO, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced it awarded an inducement grant on October 10, 2026, under BBOT's 2025 Inducement Plan as a material inducement to the employment of one individual hired by BBOT in September 2026.

BridgeBio Oncology Therapeutics, Inc (NASDAQ: BBOT - Get Free Report) has earned an average rating of "Moderate Buy" from the ten analysts that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating and nine have issued a buy rating on the company. The average 1-year price target

BridgeBio Oncology Therapeutics, Inc (NASDAQ: BBOT - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the ten ratings firms that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation and nine have issued a buy recommendation on the company. The average 12